skip to main content

Rivaroxaban renal review — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardRenal and Hepatic ImpairmentRivaroxaban renal reviewGPhC CRA

A 83-year-old woman taking rivaroxaban for AF has declining renal function and an eGFR of 24 mL/min/1.73 m². She has nosebleeds twice weekly. What monitoring is required?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Renal function review and bleeding risk assessment with the prescriber

DOACs do not need INR monitoring, but renal function and bleeding risk must be reviewed. Low eGFR and recurrent nosebleeds raise concern about dose suitability and safety. Prompt prescriber review is appropriate.

Reference: BNF